Research library

GLP1-SMA Research Overview: Molecular Pathways, Published Studies and Evidence Limitations

Compiled by:: Peptide Pilots Scientific Content Team
Reviewed by:: Peptide Pilots Quality & Compliance review
Last revised:: 3 September 2026

What does published research show about how GLP1-SMA interacts with the GLP-1 receptor, and how strong is that evidence?

GLP1-SMA is a long-acting acylated analogue of human glucagon-like peptide-1 (GLP-1) that binds the class B G-protein-coupled GLP-1 receptor (GLP1R) and stimulates cyclic-AMP accumulation in receptor-expressing cells. Its extended plasma half-life is attributed to a C18 fatty diacid side chain that promotes reversible albumin binding, together with substitution of alanine-8 by α-aminoisobutyric acid, which reduces cleavage by dipeptidyl peptidase-4. Receptor-level pharmacology is well characterised in cell systems; the interpretation of downstream physiological findings depends heavily on the model studied.

This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.

What is GLP1-SMA?

GLP1-SMA is a synthetic 31-amino-acid peptide based on the sequence of human GLP-1(7-37), modified at three positions: Aib substitution at position 8, arginine substitution at position 34, and attachment of a C18 fatty diacid linked through a γ-glutamyl/OEG spacer at lysine-26.

In laboratory work it is used as a reference GLP-1 receptor agonist for receptor-binding assays, cAMP and β-arrestin recruitment studies, islet and enteroendocrine cell culture, and rodent metabolic models. It is supplied as a lyophilised powder for reconstitution in a laboratory setting.

GLP1-SMA names and identifiers

Also referred to as: GLP1-SMA (catalogue designation); NN9535; semaglutida; GLP-1(7-37) analogue

Full chemical class	Acylated GLP-1 receptor agonist (incretin mimetic peptide)
Molecular formula	C187H291N45O59
Average molecular weight	≈4113.6 g/mol
CAS number	910463-68-2
Primary molecular target	Glucagon-like peptide-1 receptor (GLP1R), UniProt P43220
Parent hormone	Glucagon-like peptide-1, processed from proglucagon (GCG gene)
Database records	DrugBank DB13928; PubChem CID 56843331; ChEMBL CHEMBL3707348

GLP1-SMA research background

GLP-1 was identified in the early 1980s during sequencing of the proglucagon gene, and the insulinotropic activity of the truncated GLP-1(7-36)amide fragment was described later that decade. Native GLP-1 has a circulating half-life of only a few minutes because of dipeptidyl peptidase-4 (DPP-4) cleavage and renal clearance, which motivated the search for protease-resistant analogues.

GLP1-SMA was developed at Novo Nordisk as a successor to liraglutide, with the stated design objective of once-weekly dosing intervals in clinical pharmacology. The albumin-binding diacid side chain and Aib8 substitution were the two structural changes reported to drive the increase in exposure duration.

The scientific questions investigated in the published literature fall into three broad groups: receptor-level pharmacology and biased signalling; pancreatic islet and gastrointestinal physiology in animal models; and, in human trials, glycaemic and body-weight endpoints together with cardiovascular and renal outcome measures.

Proposed GLP1-SMA mechanisms and pathways

Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.

GLP1-SMA in-vitro and cell-based evidence

Binding to GLP1R in transfected cell lines activates Gαs, raising intracellular cAMP and activating protein kinase A and Epac2.
In clonal β-cell lines and isolated islets, cAMP elevation potentiates glucose-stimulated insulin secretion; the effect is glucose-dependent in these preparations, being minimal at low glucose concentrations.
Signalling-profile studies report differences between GLP-1 analogues in β-arrestin recruitment and receptor internalisation relative to cAMP production, a topic still under active investigation.

GLP1-SMA animal-model evidence

Rodent studies report reduced food intake and body weight, with evidence for signalling through GLP1R-expressing neurons in the hypothalamic arcuate nucleus and the area postrema/nucleus tractus solitarius.
Gastric-emptying delay has been observed in rodent and non-human primate models, with tachyphylaxis reported for this endpoint over repeated administration in some studies.
Rodent carcinogenicity studies with GLP-1 analogues have reported thyroid C-cell tumours; rodent C-cells express GLP1R at higher density than primate C-cells, and the cross-species relevance remains contested in the literature.

Published GLP1-SMA human-study evidence

Human pharmacokinetic studies report a terminal half-life of approximately one week, consistent with albumin-mediated distribution.
Randomised trials in type 2 diabetes and in obesity have reported reductions in HbA1c and body weight relative to placebo, and cardiovascular outcome trials have reported reductions in composite major adverse cardiovascular events in the populations studied.
Mechanistic human studies attribute weight-related findings mainly to reduced energy intake rather than increased energy expenditure, though the relative contribution of gastric emptying versus central appetite signalling is not fully resolved.

Published GLP1-SMA studies

Selected published studies involving GLP1-SMA
Study	Model / type	Research question	Main observation	Citation
Lau et al., discovery and pharmacology of GLP1-SMA	In vitro receptor assays, rodent pharmacokinetics	Which structural modifications extend GLP-1 receptor agonist exposure?	Reported albumin affinity and DPP-4 resistance conferred by the C18 diacid and Aib8 substitution, with retained GLP1R potency.	Journal of Medicinal Chemistry, 2015
STEP 1 randomised trial	Human, 1961 adults with overweight or obesity, 68 weeks	What is the effect on body weight versus placebo?	Mean change in body weight of −14.9% versus −2.4% with placebo; gastrointestinal adverse events were the most frequent.	New England Journal of Medicine, 2021
SUSTAIN-6 cardiovascular outcome trial	Human, 3297 participants with type 2 diabetes, 104 weeks	What is the cardiovascular event profile?	Lower rate of the composite primary cardiovascular endpoint versus placebo; an increased rate of retinopathy complications was reported.	New England Journal of Medicine, 2016
SELECT outcome trial	Human, 17,604 participants with obesity and established cardiovascular disease	Do effects extend to participants without diabetes?	Reduced incidence of the composite cardiovascular endpoint over a mean 39.8 months of follow-up.	New England Journal of Medicine, 2023
Blundell et al., appetite and energy intake	Human crossover mechanistic study	Is reduced intake or increased expenditure the dominant contributor?	Lower ad-libitum energy intake and altered appetite ratings; resting energy expenditure was not increased.	Diabetes, Obesity and Metabolism, 2017

Limitations of the GLP1-SMA evidence

Most high-quality human evidence comes from manufacturer-sponsored randomised trials with selected populations, protocolised titration and comparatively short follow-up relative to the chronic conditions studied.
Trial populations under-represent several groups, and effect sizes observed under trial conditions are not automatically transferable to other populations or settings.
Rodent thyroid C-cell findings have no established primate counterpart, but the absence of long-duration primate carcinogenicity data means the question remains open rather than resolved.
Mechanistic separation of central appetite signalling from peripheral gastric effects is incomplete; gastric-emptying effects appear to attenuate over time while intake effects persist, and this discrepancy is not fully explained.
Long-term durability after discontinuation is limited: extension data report substantial regression of trial endpoints after treatment withdrawal, indicating the studied effects are exposure-dependent.
In-vitro potency values differ between assay systems (cAMP versus β-arrestin, transfected versus primary cells), so cross-study potency comparisons should be made with caution.

GLP1-SMA laboratory characteristics

Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.

Appearance	White to off-white lyophilised powder
Solubility	Reported soluble in water and in aqueous buffers at mildly alkaline pH; poorly soluble near its isoelectric point
Lyophilised storage	Commonly stored at −20 °C, protected from light and moisture
Reconstituted handling	Peptide solutions are generally handled cold and protected from repeated freeze–thaw cycles
Analytical testing	Identity and purity typically assessed by RP-HPLC with UV detection and by mass spectrometry (ESI-MS or MALDI-TOF)
Stability considerations	Aggregation and deamidation are the degradation routes most often reported for acylated GLP-1 analogues

Frequently asked GLP1-SMA research questions

What receptor does GLP1-SMA act on?

The glucagon-like peptide-1 receptor (GLP1R), a class B G-protein-coupled receptor expressed in pancreatic islets, the gastrointestinal tract and several central nervous system nuclei.

Why is GLP1-SMA longer-acting than native GLP-1?

Two published structural reasons: an Aib substitution at position 8 that reduces DPP-4 cleavage, and a C18 fatty diacid side chain that promotes reversible albumin binding and slows renal clearance.

Is GLP1-SMA the same molecule as GLP2-TPT?

No. GLP1-SMA is a single-receptor GLP-1 agonist. GLP2-TPT is a GIP-based peptide that activates both the GIP and GLP-1 receptors and has a different sequence, molecular weight and receptor profile.

What analytical documentation accompanies a research batch?

Peptide Pilots supplies a batch certificate of analysis with RP-HPLC purity and mass-spectrometric identity data for the specific lot shipped.

Is this compound approved for human use by Peptide Pilots?

No. Material supplied by Peptide Pilots is for controlled laboratory research only and is not for human or veterinary use, regardless of the regulatory status of pharmaceutical products containing the same molecule.

GLP1-SMA primary references

Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue GLP1-SMA. Journal of Medicinal Chemistry. View source
Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-weekly GLP1-SMA in adults with overweight or obesity (STEP 1). New England Journal of Medicine. View source
Marso SP, Bain SC, Consoli A, et al. (2016). GLP1-SMA and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. View source
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). GLP1-SMA and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. View source
Blundell J, Finlayson G, Axelsen M, et al. (2017). Effects of once-weekly GLP1-SMA on appetite, energy intake and energy expenditure. Diabetes, Obesity and Metabolism. View source
PubMed literature index (2026). Current indexed literature for GLP1-SMA. US National Library of Medicine. View source

Authorship and revision

Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published 14 August 2026; last revised 3 September 2026. Pages are revised when the cited literature changes materially.

Catalogue reference

Peptide Pilots supplies GLP1-SMA as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.

View GLP1-SMA catalogue entry